Ellen Kim
Family Medicine · Philadelphia, PANPI 1912069329
Payments from drug & device makers
Across 205 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$778
- Lilly USA, LLC$467
- Novo Nordisk$381
- Bausch Health US, LLC$299
- Amgen$234
- Merck$231
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,436100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $778 |
| Lilly USA, LLC | 26 | $467 |
| Novo Nordisk | 23 | $381 |
| Bausch Health US, LLC | 16 | $299 |
| Amgen | 14 | $234 |
| Merck | 14 | $231 |
| Kowa Pharmaceuticals America, Inc. | 12 | $148 |
| Amarin Pharma, Inc. | 8 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $122 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $79 |
| AstraZeneca | 5 | $69 |
| Pfizer | 3 | $59 |
| Exact Sciences | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Boehringer Ingelheim | 3 | $56 |
| Boston Scientific | 1 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Novartis | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $29 |
| Dexcom, Inc. | 1 | $24 |
| Impel Pharmaceuticals Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Vistapharm, Inc. | 1 | $13 |
| Phadia US Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
How this compares
$3,436 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 154 | $190,026 |
| EliquisApixaban | 89 | $92,998 |
| JardianceEmpagliflozin | 41 | $54,984 |
| FarxigaDapagliflozin Propanediol | 60 | $52,634 |
| OzempicSemaglutide | 49 | $51,963 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $48,817 |
| JanuviaSitagliptin Phosphate | 43 | $30,149 |
| RybelsusSemaglutide | 21 | $28,891 |
| XareltoRivaroxaban | 30 | $28,439 |
| MyrbetriqMirabegron | 38 | $27,597 |
| LinzessLinaclotide | 23 | $19,536 |
| Varenicline Tartrate | 51 | $19,312 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 86 | $13,046 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 389 | $10,138 |
| VascepaIcosapent Ethyl | 20 | $8,852 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $467 | $190,026154 claims |
| PfizerEliquis | $59 | $92,99889 claims |
| Novo NordiskOzempic, Rybelsus | $381 | $80,85470 claims |
| Boehringer IngelheimJardiance, Tradjenta | $56 | $61,18053 claims |
| AstraZenecaFarxiga, Symbicort | $69 | $57,27074 claims |
| MerckJanuvia | $231 | $30,14943 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $27,59738 claims |
| AbbVieLinzess | $778 | $19,53623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Philadelphia
- Daniel LinPhiladelphia$392K
- Glenn RosenPhiladelphia$367K
- Christopher ChambersPhiladelphia$350K
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.